Thrombocytopenia and a New Deep Vein Thrombosis on Postoperative Day Seven
A 66-year-old man is on the cardiac surgery ward on day 7 after coronary artery bypass grafting. He has received subcutaneous unfractionated heparin 5000 units twice daily since surgery, plus heparin flushes. His platelet count was 260 x 10^9/L before surgery and has fallen to 85 x 10^9/L today; the value is confirmed on a repeat sample. He now has new swelling of the right calf, and compression ultrasonography shows a popliteal deep vein thrombosis. He has no bleeding, and his renal function is normal (creatinine 0.9 mg/dL). His only other medications are aspirin 81 mg, metoprolol, atorvastatin, and acetaminophen. The pretest probability score for heparin-induced thrombocytopenia is 6 points, which is high. He asks whether the heparin dose should simply be increased to treat the clot.
1. What is the diagnosis, what immediate actions are required, and why is increasing the heparin dose dangerous?
Read the worked answer
This is heparin-induced thrombocytopenia with thrombosis: a greater than 50% platelet fall beginning 5-10 days after heparin exposure, in a postoperative cardiac surgery patient, with a high 4T score and a new objectively confirmed venous thrombosis. HIT is a prothrombotic, immune-mediated reaction in which IgG antibodies against platelet factor 4-heparin complexes activate platelets and generate thrombin. Increasing the heparin dose would worsen the reaction and is exactly the wrong move.
Immediate actions: stop all heparin, including subcutaneous doses, intravenous line flushes, and heparin-coated catheters, and stop any low-molecular-weight heparin. Send a platelet factor 4/heparin immunoassay, with a serotonin release assay if confirmation is needed, but do not wait for results to start treatment. Start a non-heparin anticoagulant at therapeutic dose. Document heparin allergy and HIT prominently in the chart and notify pharmacy and the surgical team. Avoid vitamin K and do not start warfarin alone. Continue aspirin if there is a coronary stent or bypass indication, and obtain baseline coagulation studies and a platelet count every 1-2 days until recovery.
2. Which alternative anticoagulant would you choose, how would you monitor it, and when would warfarin be introduced?
Read the worked answer
Acceptable options are argatroban, bivalirudin, danaparoid (where available), or fondaparinux; low-molecular-weight heparin is contraindicated. This patient has normal renal function, so any of these is reasonable. Argatroban is a direct thrombin inhibitor cleared hepatically and is monitored with the aPTT, aiming for 1.5-3 times baseline; it raises the INR, which complicates warfarin overlap. Bivalirudin is cleared partly renally and also monitored by aPTT. Fondaparinux is convenient and given subcutaneously but is off-label for HIT in some jurisdictions, so local policy matters.
Warfarin should not be started until the platelet count has recovered to at least 150 x 10^9/L, because starting it during the acute prothrombotic phase can cause venous limb gangrene and warfarin-induced skin necrosis. When the platelet count recovers, start a low dose (about 5 mg) with at least five days of overlap with the parenteral agent, and continue until the INR is greater than 2 for two consecutive days; interpret the INR cautiously because argatroban inflates it, and use a chromogenic factor X level if needed. Anticoagulation should continue for about 3 months for HIT with thrombosis, or longer if another indication exists.
3. Should he receive a platelet transfusion at 85 x 10^9/L, and how should future heparin exposure and possibly future cardiac surgery be handled?
Read the worked answer
No. Prophylactic platelet transfusion is generally avoided in HIT because transfused platelets can be activated by the circulating antibodies and may fuel thrombosis; the platelet count is not low enough to cause spontaneous bleeding. Reserve transfusion for active bleeding or before an invasive procedure with severe thrombocytopenia, and give it in consultation with hematology.
For the future: avoid all heparin, including flushes and heparin-bonded catheters, and record this as a true allergy-like contraindication. HIT antibodies typically become undetectable after about 100 days, so if he ever needs cardiac surgery again, the operation should ideally be deferred beyond that window, antibodies should be rechecked and documented as negative, and the procedure planned with a non-heparin anticoagulant such as bivalirudin for cardiopulmonary bypass. If urgent surgery is unavoidable during the acute phase, it should be done at a center experienced with heparin-free bypass. Plan hematology follow-up, and counsel him to tell every future clinician about the reaction.